View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 18, 2020updated 12 Jul 2022 11:44am

CureVac to trial Covid-19 vaccine in Germany and Belgium

CureVac has secured approval from the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) for Phase I clinical trial of its Covid-19 vaccine candidate, named CVnCoV.

CureVac has secured approval from the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) for Phase I clinical trial of its Covid-19 vaccine candidate, named CVnCoV.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Designed as a mRNA vaccine, CureVac’s product uses nucleotides without chemical modifications in the mRNA to generate a strong immune response. The mRNA encodes the spike protein of SARS-CoV-2 and is made up of lipid nanoparticles (LNP).

CureVac started works for developing a Covid-19 vaccine candidate earlier this year. Following characterisation of multiple potential candidates, CVnCoV was finalised for further development.

The selection process considered humoral and cellular immunogenicity data, balanced immune-response, and speed and capability for large scale manufacturing, said the company.

CureVac acting CEO Dr Franz-Werner Haas said: “During the last few months our team has put a lot of efforts into the preclinical validation of several vaccine candidates to select an optimal construct.

“We are confident that our early optimisation work will provide a safe and effective low dose vaccine. In parallel, we are already producing large quantities of this trial medication under GMP conditions.”

The Phase 1 dose escalation trial will assess a dose range of 2µg to 8µg in 168 healthy volunteers aged 18 to 60 years. The objective is to establish the optimal dose while investigating the safety and immune profile of the vaccine candidate.

First participants will receive the vaccine at the Institute for Tropical Medicine in Tübingen, Germany; Ghent University Hospital in Belgium; Tropical Institute of the University Hospital Munich, LMU in Germany; and Hannover Medical School in Germany.

CureVac chief technology officer Dr Mariola Fotin-Mleczek said: “The data we generated in various animal models indicated that the vaccine candidate induces high virus neutralising antibody titers compared to sera from patients who recovered from Covid-19 disease.

“Immune response induced by our vaccine candidate was well balanced and included the generation of spike protein specific T cell responses. We now look forward to confirm these results in humans.”

The company secured financial support from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop the vaccine candidate.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena